Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 96

1.

Small subgroup of aggressive, highly proliferative prostatic carcinomas defined by p53 accumulation.

Visakorpi T, Kallioniemi OP, Heikkinen A, Koivula T, Isola J.

J Natl Cancer Inst. 1992 Jun 3;84(11):883-7.

PMID:
1350643
3.
4.

p53 protein accumulation and gene mutation in the progression of human prostate carcinoma.

Navone NM, Troncoso P, Pisters LL, Goodrow TL, Palmer JL, Nichols WW, von Eschenbach AC, Conti CJ.

J Natl Cancer Inst. 1993 Oct 20;85(20):1657-69.

PMID:
7692074
5.

Polymorphous low-grade adenocarcinoma: flow cytometric, p53, and PCNA analysis.

Kelsch RD, Bhuiya T, Fuchs A, Gentile P, Kahn MA, Fantasia JE.

Oral Surg Oral Med Oral Pathol Oral Radiol Endod. 1997 Oct;84(4):391-9.

PMID:
9347503
6.

p53 nuclear protein accumulation correlates with mutations in the p53 gene, tumor grade, and stage in bladder cancer.

Esrig D, Spruck CH 3rd, Nichols PW, Chaiwun B, Steven K, Groshen S, Chen SC, Skinner DG, Jones PA, Cote RJ.

Am J Pathol. 1993 Nov;143(5):1389-97.

7.

Accumulation of p53 tumor suppressor gene protein: an independent marker of prognosis in breast cancers.

Thor AD, Moore DH II, Edgerton SM, Kawasaki ES, Reihsaus E, Lynch HT, Marcus JN, Schwartz L, Chen LC, Mayall BH, et al.

J Natl Cancer Inst. 1992 Jun 3;84(11):845-55.

PMID:
1317462
8.

Inverted urothelial papilloma: is ploidy, MIB-1 proliferative activity, or p53 protein accumulation predictive of urothelial carcinoma?

Cheville JC, Wu K, Sebo TJ, Cheng L, Riehle D, Lohse CM, Shane V.

Cancer. 2000 Feb 1;88(3):632-6.

PMID:
10649258
9.

Immunohistochemical analysis of proliferating cell nuclear antigen, p53 protein and nm23 protein, and nuclear DNA content in transitional cell carcinoma of the bladder.

Shiina H, Igawa M, Nagami H, Yagi H, Urakami S, Yoneda T, Shirakawa H, Ishibe T, Kawanishi M.

Cancer. 1996 Oct 15;78(8):1762-74.

10.

DNA ploidy and p53 expression correlate with survival and cell proliferative activity in male breast carcinoma.

Pich A, Margaria E, Chiusa L, Ponti R, Geuna M.

Hum Pathol. 1996 Jul;27(7):676-82.

PMID:
8698311
11.

Proliferating cell nuclear antigen (PCNA), immunostaining and flow cytometric DNA analysis of renal cell carcinoma.

Tanioka F, Hiroi M, Yamane T, Hara H.

Zentralbl Pathol. 1993 Aug;139(3):185-93.

PMID:
8105885
12.

Association of p53 protein expression with tumor cell proliferation rate and clinical outcome in node-negative breast cancer.

Allred DC, Clark GM, Elledge R, Fuqua SA, Brown RW, Chamness GC, Osborne CK, McGuire WL.

J Natl Cancer Inst. 1993 Feb 3;85(3):200-6.

PMID:
8423624
14.
16.

Mutated p53 protein expression and proliferative activity in advanced gastric cancer.

Ikeguchi M, Saito H, Kondo A, Tsujitani S, Maeta M, Kaibara N.

Hepatogastroenterology. 1999 Jul-Aug;46(28):2648-53.

PMID:
10522058
18.

The expression of proliferating cell nuclear antigen in paraffin sections of peripheral, node-negative non-small cell lung cancer.

Fontanini G, Macchiarini P, Pepe S, Ruggiero A, Hardin M, Bigini D, Vignati S, Pingitore R, Angeletti CA.

Cancer. 1992 Sep 15;70(6):1520-7.

19.

Can p53 nuclear over-expression, Bcl-2 accumulation and PCNA status be of prognostic significance in high-risk superficial and invasive bladder tumours?

Plastiras D, Moutzouris G, Barbatis C, Presvelos V, Petrakos M, Theodorou C.

Eur J Surg Oncol. 1999 Feb;25(1):61-5.

PMID:
10188857
20.

Nuclear overexpression of p53 protein in transitional cell bladder carcinoma: a marker for disease progression.

Sarkis AS, Dalbagni G, Cordon-Cardo C, Zhang ZF, Sheinfeld J, Fair WR, Herr HW, Reuter VE.

J Natl Cancer Inst. 1993 Jan 6;85(1):53-9.

PMID:
7677935

Supplemental Content

Support Center